COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,832 Articles (22,553 medRxiv, 8,279 bioRxiv)

Most recent first Previous |  Page 753: Articles 7521-7530  | Next

SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity
Manali, M., Bissett, L. A., Amat, J., Logan, N., Scott, S., Hughes, E., Harvey, W., Orton, R., Thomson, E., Gunson, R., Viana, M., Willett, B., Murcia, P. R.
10.1101/2022.05.06.490867 — Posted: 2022-05-06
Allelic gene polymorphisms suspected to diversify the individual early metabolic response upon influenza H3N2 and SARS-CoV-2 infections
Arnholdt-Schmitt, B., Aziz, S., Costa, J. H.
10.1101/2022.05.05.490776 — Posted: 2022-05-06
GDF15 and ACE2 stratify COVID19 patients according to severity while ACE2 mutations increase infection susceptibility.
Torrens-Mas, M., Perello-Reus, C. M., Trias-Ferrer, N., Ibarguen-Gonzalez, L., Crespi, C., Galmes-Panades, A. M., Navas-Enamorado, C., Sanchez-Polo, A., Pierola-Lopetegui, J., Masmiquel, L., Socias Crespi, L., Barcelo, C., Gonzalez-Freire, M.
10.1101/2022.05.06.490907 — Posted: 2022-05-06
Reaction Conditions Promoting the Specific Detection of SARS-CoV-2 NendoU Enzymatic Activity
Makharashvili, N., McNamara, J. O.
10.1101/2022.05.06.490915 — Posted: 2022-05-06
ORF6 protein of SARS-CoV-2 inhibits TRIM25 mediated RIG-I ubiquitination to mitigate type I IFN induction.
Khatun, O., Sharma, M., Narayan, R., Tripathi, S.
10.1101/2022.05.05.490850 — Posted: 2022-05-06
Immunological findings in a group of individuals who were non-responders to standard two-dose SARS-CoV-2 vaccines
Zeng, Q., Yang, X., Gao, Q., Lin, B.-y., Li, Y.-z., Huang, G., Xu, Y.
10.1101/2022.05.05.490815 — Posted: 2022-05-06
Modelling the within-host spread of SARS-CoV-2 infection, and the subsequent immune response, using a hybrid, multiscale, individual-based model. Part I: Macrophages.
Rowlatt, C. F., Chaplain, M. A. J., Hughes, D. J., Gillespie, S. H., Dockrell, D. H., Johannessen, I., Bowness, R.
10.1101/2022.05.06.490883 — Posted: 2022-05-06
ACE2 nanoparticles prevent cell entry of SARS-CoV-2
Sauvanet, C., Lemos, M., Bezault, A., Rodriguez de Francisco, B., Chan, M. C., Hui, K. P., Ng, K.-c., Nicholls, J. M., Volkmann, N., Hanein, D.
10.1101/2022.05.05.490805 — Posted: 2022-05-06
Protection against omicron severe disease 0-7 months after BNT162b2 booster
Amir, O., Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Alroy-Preis, S., Ash, N., Huppert, A., Milo, R.
10.1101/2022.05.04.22274647 — Posted: 2022-05-05
The spread and burden of the COVID-19 pandemic in sub-Saharan Africa: comparison between predictions and actual data and lessons learned.
Fokoua-Maxime, C. D., Bellouche, Y., Tchigui-Ariolle, D. N., Tchato-Yann, T. L., Choukem, S. P.
10.1101/2022.05.04.22274692 — Posted: 2022-05-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).